지난 12월 1일 “한국 바이오 기업들이 매사추세 주 (보스톤) 진출에 이로운 이점과 전략” 을 주제로 4th KAPAL On-Air webinar가 진행되었습니다.
보스톤시에서 제공하는 다양한 혜택과 정보들을 안내드리고, 보스톤 이미 정착해 성장하고 있는 한국기업들 (GENESCO, ORUM Therapeutics, and INGENIA Therapeutics) 초청하여 다양한 사례를 들어보는 시간을 가졌습니다. 더불어 매스바이오 (Mass Bio)에 Ben Bradford (Vice President)가 보스톤 생명과학기업 현황에 대해 발표 드렸습니다.
회원 여러분들의 많은 관심과 도움으로 각 Webinar에 260여명이 참석하셔서 많은 질의 응답이 진행되는 등 성황리에 완료 되었습니다.
4th KAPAL On-Air webinar materials (Presentation slides and recordings)은 아래 링크를 통하여 다운로드하시거나 재 시청하실 수 있습니다.
도움 주시고 참여해주신 모든 분들께 다시 한번 감사의 인사를 드립니다.
Jong Sung Koh, Ph.D.
CEO at GENOSCOS
Dr. Jong Sung Koh is the CEO at GENOSCO (www.genosco.com ), Inc. with Ph.D. degree from California Institute of Technology (Caltech). Prior to GENOSCO, he served as the vice president and member of the executive management team at LG Life Sciences from 2002 to 2007 in Korea and head of the Anti-cancer Research Center at Korea Research Institute of Chemistry and Technology (KRICT, 2007-2008). He has over 30 years of pharmaceutical industry experience, during which his works have led to identification of drug and numerous drug candidates, including Gemigliptin (Zemiglo), a successfully marketed drug in Korea for the treatment of diabetes (90 million dollar sales in Korea), historic record sales in Korean drug discovery history and Lazertinib, a lung cancer drug that was licensed to J&J’s Janssen valued up to 1.25 billion dollars. Lazertinib is in pivotal trial for the approval of FDA in non-small cell lung cancer. Dr. Koh founded Korean American Bio Industrial Council (KABIC: www.kabic.org ), a non-profit organization headquartered in Boston, Massachusetts, in 2011. KABIC becomes a main network hub for Korean and Korea-American healthcare professionals and enterprises. He served as the president for 7 years and is serving as a special advisor since 2018.
Sung Joo Lee, Ph.D.
CEO at Orum Therapeutics
Orum Therapeutics is a private biotech company located in Daejeon, Korea, and Cambridge, Massachusetts. We are developing a novel class of therapeutic antibodies to bring new medicines to patients with unmet medical needs. Orum (오름) means ‘ascent’ in Korean, and it represents to us the idea of climbing or moving upwards. In 2016, we were founded with the goal of discovering the antibodies against undruggable targets. We named our company Orum, because we believe that inhibiting undruggable targets with antibody drugs is akin to climbing K2, one of the most dangerous mountains in the world. K2 was insurmountable for nearly 100 years, until its first climbers used oxygen tanks in 1952. We believe Orum possesses the ‘oxygen tank,’ but requires further perseverance, determination and teamwork in order to complete our ascent.
Our vision is a world where no patient suffers from diseases caused by undruggable targets.
Sangyeul Han, Ph.D.
CEO/Co-founder, INGENIA Therapeutics Inc., USA
Sangyeul Han is currently the Co-Founder & CEO at INGENIA Therapeutics Inc., a biotech startup, established to develop innovative therapeutic antibodies. He received his B.S., M.S., and Ph.D. degrees in Molecular Biology from Seoul National University, South Korea, where his research focused on investigating the regulatory mechanism of secretory protein trafficking. In 2002, he started his postdoctoral research at the Massachusetts General Hospital/Harvard Medical School where he studied the pathological mechanisms of several tumor suppressor syndromes, including Tuberous Sclerosis Complex (TSC), Neurofibromatosis (NF), and chordomas as a research fellow/instructor. In 2010, he then joined the Biotherapeutics lab at Samsung Advanced Institute of Technology, South Korea, where he led a project for the development of therapeutic antibodies for multiple diseases. In 2016, he moved to Cell Signaling Technology, USA, where he led Antibody Technology group & Molecular Biology group. He is an author of 20+ publications in scientific journals and an inventor on multiple patents in the area of therapeutic antibody development. His expertise lies in R&D of therapeutic antibodies, vascular biology, & cancer biology.
Ben Bradford
Vice President of Membership and Economic Development, MassBio
Ben joined the MassBio team in 2017. As Vice President of Membership and Economic Development, he oversees the recruitment of new member companies and the Member Services team’s efforts to maximize the membership needs of existing members. He also works with member and non-member companies to support their decision making on relocation or expansions. Through relationships with foreign economic development agencies, Ben works to connect foreign companies to the US market. Prior to MassBio, Ben worked as Director of Business Development and Regional Strategy at the Massachusetts Life Sciences Center where he was responsible for recruiting new companies to do business in Massachusetts and developing relationships with municipalities across the Commonwealth with the goal of expanding the industry state-wide. Ben has a B.A. in Political Science from Union College(NY). He lives in North Reading with his wife and two kids.
